NASDAQ · SRZN
Healthcare · Biotechnology
$16.93
Down-$0.08 (-0.49%)
Updated Sep 17, 2026, 4:49 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SRZN closed at $16.93 after 20 trading sessions, down 29.49% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $17.84 | $17.86 | $16.78 | $16.93 | 116.74K |
| Sep 15, 2026 | $17.81 | $18.34 | $17.15 | $17.77 | 151.94K |
| Sep 14, 2026 | $19.03 | $19.29 | $17.61 | $17.84 | 198.2K |
| Sep 11, 2026 | $19.68 | $19.72 | $18.71 | $19.00 | 145.34K |
| Sep 10, 2026 | $19.95 | $20.15 | $18.995 | $19.45 | 277.75K |
| Sep 9, 2026 | $20.52 | $20.52 | $18.40 | $20.03 | 206.97K |
| Sep 8, 2026 | $22.57 | $23.18 | $20.63 | $20.68 | 202.33K |
| Sep 4, 2026 | $22.34 | $22.90 | $21.535 | $22.76 | 150.24K |
| Sep 3, 2026 | $22.92 | $22.99 | $22.24 | $22.54 | 200.87K |
| Sep 2, 2026 | $22.32 | $23.005 | $21.895 | $22.60 | 116.91K |
| Sep 1, 2026 | $21.72 | $22.475 | $21.651 | $22.20 | 124.63K |
| Aug 31, 2026 | $22.28 | $22.62 | $21.45 | $22.02 | 266.75K |
| Aug 28, 2026 | $23.75 | $23.75 | $22.08 | $22.42 | 239.36K |
| Aug 27, 2026 | $23.69 | $24.87 | $23.03 | $24.01 | 340.75K |
| Aug 26, 2026 | $23.52 | $24.16 | $23.19 | $23.71 | 128.75K |
| Aug 25, 2026 | $23.97 | $25.01 | $23.29 | $23.36 | 218.97K |
| Aug 24, 2026 | $23.81 | $24.33 | $22.80 | $23.97 | 163.64K |
| Aug 21, 2026 | $23.73 | $25.01 | $23.49 | $23.99 | 149.72K |
| Aug 20, 2026 | $24.46 | $24.46 | $23.085 | $23.50 | 135.33K |
| Aug 19, 2026 | $24.44 | $24.50 | $23.77 | $24.01 | 122.46K |
The latest Smart Investors Daily articles mentioning SRZN.
SRZN research
Company profile and research snapshot.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | William Blair | Outperform | — |
| Aug 10, 2026 | HC Wainwright & Co. | Buy | — |
| May 7, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 21, 2026 | TD Cowen | Buy | — |
| Mar 24, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Surrozen, Inc. (SRZN) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 1:50 PM EDTCompany ParticipantsCraig Parker - CEO,...
Yahoo · Sep 8, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration seeking to evaluate SZN-8141, a bifunctional Wnt agonist and vascular endo
Benzinga · Sep 8, 2026
Surrozen, Inc. (Surrozen or the Company) (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening
Yahoo · Sep 2, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at two upcoming healthcare investor conferences. 2026 Cantor Global Healthcare Conference on Thursday, September 10, 2026 Fireside Chat at
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SRZN.
